Pharmanutra

Board/Management Information • Mar 26, 2025

Informazione Regolamentata n. 20106-16-2025	Data/Ora Inizio Diffusione 26 Marzo 2025 14:38:47		Euronext Star Milan
	:
Societa'		PHARMANUTRA
Identificativo Informazione Regolamentata	:	202964
Utenza - Referente	:	PHARMANUTRAN04 - Roberto Lacorte
Tipologia	:	REGEM; 3.1
Data/Ora Ricezione	:	26 Marzo 2025 14:38:47
Data/Ora Inizio Diffusione	:	26 Marzo 2025 14:38:47
Oggetto	:	Publication of the lists submitted for the appointment of the Board of Statutory Auditors
Testo del comunicato

Vedi allegato

PHARMANUTRA S.P.A.:

PUBLICATIONOF THE LISTS SUBMITTED FOR THE APPOINTMENT OF THE BOARD OF STATUTORY AUDITORS AND RELATED PROPOSALS FOR DELIBERATION

Pisa, 26 March 2025 – With reference to the Shareholders' Meeting of Pharmanutra S.p.A. (the "Company") convened for 16 April 2025 at 11:00 a.m., in a single call, the Company announces that, within the terms of the law and the Articles of Association, 2 slates have been submitted for the appointment of the Board of Statutory Auditors referred to in item 3 of the agenda, as follows:

List no. 1 submitted by the shareholder ALH S.r.l. (holder of a total shareholding equal to 31.384% of the share capital):

Section I - Standing Auditors

• 1. Giuseppe Rotunno (*)
• 1. Debora Mazzaccherini
• 1. Michele Luigi Giordano

(*) Indicates the candidate for the office of Chairman of the Board of Statutory Auditors if taken from this list

Section II – Alternate Auditors

• 1. Elena Pro
• 1. Alessandro Lini

List no. 2 submitted by institutional investors representing a total of 2.31078% of the share capital:

Section I - Standing Auditors

1. Raffaele Ripa

Section II - Alternate Auditors

1. Cecilia Andreoli

It should be noted that the documentation accompanying List no. 2 for the appointment of the Board of Statutory Auditors also contains the declaration of the shareholders submitting the absence of any relationship and/or significant relationships, also pursuant to Consob Communication no. DEM/9017893 of 26 February 2009, with the shareholders who – on the basis of the communications of significant shareholdings pursuant to Article 120 of Legislative Decree 58/1998 (the "TUF") or the publication of the relevant shareholders' agreements pursuant to art. 122 of the TUF – hold, also jointly, a controlling or relative majority shareholding as provided for by art. 148, paragraph 2, of the TUF and 144-quinquies of the Issuers' Regulation adopted by resolution no. 11971/1999.

It should also be noted that the shareholder ALH S.r.l. has also filed, within the terms and in the manner provided for by law, the resolution proposals regarding the appointment of the Chairman of the Board of Statutory Auditors if taken from the list presented by the same shareholder and the determination of the remuneration of the members of the Board of Statutory Auditors referred to in items 3.2 and 3.3 respectively on the agenda of the ordinary part of the Shareholders' Meeting.

The slates, accompanied by the documentation required by the applicable provisions, including the Articles of Association, and the resolution proposals submitted by the shareholder ALH S.r.l. (items 3.2 and 3.3 on the agenda of the Shareholders' Meeting), are available at the Company's registered office, on the Company' s website (www.pharmanutra.it, Section "Governance / Shareholders' Meetings section") and at the authorised storage mechanism "eMarket Storage".

PharmaNutra S.p.A.

Founded and led by the President Andrea Lacorte and Vice President Roberto Lacorte, PharmaNutra was established in 2003. It develops unique nutritional supplements and innovative nutritional devices, handling the entire production process, from proprietary raw materials to finished product. PharmaNutra is a leader in the production of iron-based nutritional supplements with the SiderAL® brand, where it can claim important Sucrosomial® Technology patents, and is considered one of the top players in the sector of medical devices dedicated to the restoration of joint capacity thanks to the Cetilar® brand, now on the market also with Cetilar® Nutrition, a line of supplements designed for those who practice sport constantly. Over the years the Group - present abroad in over 89 countries - has developed precise strategy for the management and production of intellectual property, founded on the integrated management of all the various elements: proprietary raw materials, patents, brands and clinical evidence.

PharmaNutra.it

Per information:

PharmaNutra S.p.A. Ufficio Stampa - Spriano Communication & Partners

PharmaNutra S.p.A. Sede Legale Via Campodavela, 1 - 56122 Pisa | +39 050 7846500 pharmanutra.it | info@pharmanutra.it | pharmanutra@pec.it C.F. / P.Iva / Reg. Impr. 01679440501 - Codice SDI SUBM70N Cap.Soc. € 1.123.097,70 I.V. | REA 146259

Via Campodavela 1 - 56122 Pisa

Tel. +39 050 7846500

investorrelation@pharmanutra.it

Ufficio Stampa Interno

press@calabughi.com

Via Santa Radegonda, 16 - 20121 Milano

Tel. +39 02 83635708

Matteo Russo mrusso@sprianocommunication.com Cristina Tronconi

ctronconi@sprianocommunication.com

PharmaNutra S.p.A.

Sede Legale Via Campodavela, 1 - 56122 Pisa | +39 050 7846500 pharmanutra.it | info@pharmanutra.it | pharmanutra@pec.it C.F. / P.Iva / Reg. Impr. 01679440501 - Codice SDI SUBM70N Cap.Soc. € 1.123.097,70 I.V. | REA 146259

Fine Comunicato n.20106-16-2025 Numero di Pagine: 5
--------------------------------------------------------